Vergent Bioscience Australia

Vergent Bioscience is a clinical-stage biotechnology company developing tumor-targeted imaging agents designed to help surgeons see and remove difficult-to-find Glandular and Solid tumors. The company's lead candidate, VGT-309, is a small molecule fluorescent tracer that binds irreversibly to cathepsins, a family of proteases overexpressed in a wide range of solid tumors. By providing real-time, high-resolution visualization of tumor margins and occult disease, Vergent aims to improve surgical outcomes and reduce the need for follow-up procedures. The company operates a subsidiary in Australia to facilitate clinical development and leverage the region's clinical trial infrastructure.